RAS作用薬のグローバル市場（2023-2031年）：ACE阻害薬、アンジオテンシンII受容体拮抗薬[ARB]、レニン阻害薬、アルドステロン拮抗薬、その他

• 英文タイトル：RAS-acting Agents Market (Drug Class: ACE Inhibitors, Angiotensin II Receptor Blockers [ARBs], Renin Inhibitors, Aldosterone Antagonists, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

• レポートコード：MRC2307A0124 • 出版社/出版日：Transparency Market Research / 2023年4月 • レポート形態：英文、PDF、209ページ • 納品方法：Eメール • 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥857,660 (USD5,795)	▷ お問い合わせ
Multi User	￥1,301,660 (USD8,795)	▷ お問い合わせ
Corporate License	￥1,745,660 (USD11,795)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

Transparency Market Research社の本報告書は、世界のRAS作用薬市場規模が、2023年の97億ドルから予測期間中、年平均4.2％で成長し、2031年には134億ドルに達すると予測しています。本書は、序論、仮定＆調査手法、エグゼクティブサマリー、市場概要、キーインサイト、薬物クラス別（ACE阻害薬、アンジオテンシンII受容体拮抗薬[ARB]、レニン阻害薬、アルドステロン拮抗薬、その他）分析、疾患別（高血圧、心不全、慢性腎臓病、糖尿病性腎症、冠動脈疾患）分析、流通チャンネル別（病院薬局、小売薬局、オンライン薬局）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などの構成でまとめています。なお、当市場の主要企業には、Novartis AG、Pfizer, Inc.、AstraZeneca plc、Merck & Co., Inc.、Sanofi S.A.、Bristol-Myers Squibb Company、Daiichi Sankyo Company, Limited、Takeda Pharmaceutical Company Limited、Boehringer Ingelheim GmbH、Johnson & Johnson、Other Prominent Playersなどがあります。 ・序論 ・仮定＆調査手法 ・エグゼクティブサマリー ・市場概要 ・キーインサイト ・世界のRAS作用薬市場規模：薬物クラス別 - ACE阻害薬の市場規模 - アンジオテンシンII受容体拮抗薬[ARB]の市場規模 - レニン阻害薬の市場規模 - アルドステロン拮抗薬の市場規模 - その他薬物クラスの市場規模 ・世界のRAS作用薬市場規模：疾患別 - 高血圧における市場規模 - 心不全における市場規模 - 慢性腎臓病における市場規模 - 糖尿病性腎症における市場規模 - 冠動脈疾患における市場規模 ・世界のRAS作用薬市場規模：流通チャンネル別 - 病院薬局チャンネルの市場規模 - 小売薬局チャンネルの市場規模 - オンライン薬局チャンネルの市場規模 ・世界のRAS作用薬市場規模：地域別 - 北米のRAS作用薬市場規模 - ヨーロッパのRAS作用薬市場規模 - アジア太平洋のRAS作用薬市場規模 - 中南米のRAS作用薬市場規模 - 中東・アフリカのRAS作用薬市場規模 ・競争状況

RAS-acting Agents Market – Scope of Report
TMR’s report on the global RAS-acting Agents Market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global RAS-acting Agents Market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global RAS-acting Agents Market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the Plasmonic Materials market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Plasmonic Materials market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Plasonic Materials market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global Plasmonic Materials market.

The report delves into the competitive landscape of the global Plasmonic Materials market. Key players operating in the global RAS-acting Agents Market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global RAS-acting Agents Market profiled in this report.

Key Questions Answered in Global RAS-acting Agents Market Report
• What is the sales/revenue generated by Plasmonic Materials across all regions during the forecast period?
• What are the opportunities in the global Plasmonic Materials market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

RAS-acting Agents Market – Research Objectives and Research Approach
The comprehensive report on the global RAS-acting Agents Market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global RAS-acting Agents Market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global Plasmonic Materials market.

レポート目次

---

1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global RAS-acting Agents Market
4. Market Overview
    4.1. Introduction
        4.1.1. Segment Definition
        4.1.2. Industry Evolution/Developments
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global RAS-acting Agents Market Analysis and Forecast, 2017–2031
5. Key Insights
    5.1. Technological Advancements
    5.2. Disease Prevalence & Incidence Rate Globally With Key Countries
    5.3. Key Industry Events
    5.4. COVID-19 Impact Analysis
6. Global RAS-acting Agents Market Analysis and Forecast, by Drug Class
    6.1. Introduction & Definition
    6.2. Key Findings/Developments
    6.3. Market Value Forecast, by Drug Class, 2017–2031
        6.3.1. ACE inhibitors
        6.3.2. Angiotensin II Receptor Blockers (ARBs)
        6.3.3. Renin Inhibitors
        6.3.4. Aldosterone Antagonists
        6.3.5. Others (diuretics)
    6.4. Market Attractiveness Analysis, by Drug Class
7. Global RAS-acting Agents Market Analysis and Forecast, by Indication
    7.1. Introduction & Definition
    7.2. Key Findings/Developments
    7.3. Market Value Forecast, by Indication, 2017–2031
        7.3.1. Hypertension
        7.3.2. Heart Failure
        7.3.3. Chronic Kidney Disease
        7.3.4. Diabetic Nephropathy
        7.3.5. Coronary Artery Disease
    7.4. Market Attractiveness Analysis, by Indication
8. Global RAS-acting Agents Market Analysis and Forecast, by Distribution Channel
    8.1. Introduction & Definition
    8.2. Key Findings/Developments
    8.3. Market Value Forecast, by Distribution Channel, 2017–2031
        8.3.1. Hospital Pharmacies
        8.3.2. Retail Pharmacies
        8.3.3. Online Pharmacies
    8.4. Market Attractiveness Analysis, by Distribution Channel
9. Global RAS-acting Agents Market Analysis and Forecast, by Region
    9.1. Key Findings
    9.2. Market Value Forecast, by Region, 2017–2031
        9.2.1. North America
        9.2.2. Europe
        9.2.3. Asia Pacific
        9.2.4. Latin America
        9.2.5. Middle East & Africa
    9.3. Market Attractiveness Analysis, by Region
10. North America RAS-acting Agents Market Analysis and Forecast
    10.1. Introduction
        10.1.1. Key Findings
    10.2. Market Value Forecast, by Drug Class, 2017–2031
        10.2.1. ACE inhibitors
        10.2.2. Angiotensin II Receptor Blockers (ARBs)
        10.2.3. Renin Inhibitors
        10.2.4. Aldosterone Antagonists
        10.2.5. Others (diuretics)
    10.3. Market Value Forecast, by Indication, 2017–2031
        10.3.1. Hypertension
        10.3.2. Heart Failure
        10.3.3. Chronic Kidney Disease
        10.3.4. Diabetic Nephropathy
        10.3.5. Coronary Artery Disease
    10.4. Market Value Forecast, by Distribution Channel, 2017–2031
        10.4.1. Hospital Pharmacies
        10.4.2. Retail Pharmacies
        10.4.3. Online Pharmacies
    10.5. Market Value Forecast, by Country, 2017–2031
        10.5.1. U.S.
        10.5.2. Canada
    10.6. Market Attractiveness Analysis
        10.6.1. By Drug Class
        10.6.2. By Indication
        10.6.3. By Distribution Channel
        10.6.4. By Country
11. Europe RAS-acting Agents Market Analysis and Forecast
    11.1. Introduction
        11.1.1. Key Findings
    11.2. Market Value Forecast, by Drug Class, 2017–2031
        11.2.1. ACE inhibitors
        11.2.2. Angiotensin II Receptor Blockers (ARBs)
        11.2.3. Renin Inhibitors
        11.2.4. Aldosterone Antagonists
        11.2.5. Others (diuretics)
    11.3. Market Value Forecast, by Indication, 2017–2031
        11.3.1. Hypertension
        11.3.2. Heart Failure
        11.3.3. Chronic Kidney Disease
        11.3.4. Diabetic Nephropathy
        11.3.5. Coronary Artery Disease
    11.4. Market Value Forecast, by Distribution Channel, 2017–2031
        11.4.1. Hospital Pharmacies
        11.4.2. Retail Pharmacies
        11.4.3. Online Pharmacies
    11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
        11.5.1. Germany
        11.5.2. U.K.
        11.5.3. France
        11.5.4. Italy
        11.5.5. Spain
        11.5.6. Rest of Europe
    11.6. Market Attractiveness Analysis
        11.6.1. By Drug Class
        11.6.2. By Indication
        11.6.3. By Distribution Channel
        11.6.4. By Country/Sub-region
12. Asia Pacific RAS-acting Agents Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast, by Drug Class, 2017–2031
        12.2.1. ACE inhibitors
        12.2.2. Angiotensin II Receptor Blockers (ARBs)
        12.2.3. Renin Inhibitors
        12.2.4. Aldosterone Antagonists
        12.2.5. Others (diuretics)
    12.3. Market Value Forecast, by Indication, 2017–2031
        12.3.1. Hypertension
        12.3.2. Heart Failure
        12.3.3. Chronic Kidney Disease
        12.3.4. Diabetic Nephropathy
        12.3.5. Coronary Artery Disease
    12.4. Market Value Forecast, by Distribution Channel, 2017–2031
        12.4.1. Hospital Pharmacies
        12.4.2. Retail Pharmacies
        12.4.3. Online Pharmacies
    12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
        12.5.1. China
        12.5.2. Japan
        12.5.3. India
        12.5.4. Australia & New Zealand
        12.5.5. Rest of Asia Pacific
    12.6. Market Attractiveness Analysis
        12.6.1. By Drug Class
        12.6.2. By Indication
        12.6.3. By Distribution Channel
        12.6.4. By Country/Sub-region
13. Latin America (LATAM) RAS-acting Agents Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast, by Drug Class, 2017–2031
        13.2.1. ACE inhibitors
        13.2.2. Angiotensin II Receptor Blockers (ARBs)
        13.2.3. Renin Inhibitors
        13.2.4. Aldosterone Antagonists
        13.2.5. Others (diuretics)
    13.3. Market Value Forecast, by Indication, 2017–2031
        13.3.1. Hypertension
        13.3.2. Heart Failure
        13.3.3. Chronic Kidney Disease
        13.3.4. Diabetic Nephropathy
        13.3.5. Coronary Artery Disease
    13.4. Market Value Forecast, by Distribution Channel, 2017–2031
        13.4.1. Hospital Pharmacies
        13.4.2. Retail Pharmacies
        13.4.3. Online Pharmacies
    13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
        13.5.1. Brazil
        13.5.2. Mexico
        13.5.3. Rest of LATAM
    13.6. Market Attractiveness Analysis
        13.6.1. By Drug Class
        13.6.2. By Indication
        13.6.3. By Distribution Channel
        13.6.4. By Country/Sub-region
14. Middle East & Africa RAS-acting Agents Market Analysis and Forecast
    14.1. Introduction
        14.1.1. Key Findings
    14.2. Market Value Forecast, by Drug Class, 2017–2031
        14.2.1. ACE inhibitors
        14.2.2. Angiotensin II Receptor Blockers (ARBs)
        14.2.3. Renin Inhibitors
        14.2.4. Aldosterone Antagonists
        14.2.5. Others (diuretics)
    14.3. Market Value Forecast, by Indication, 2017–2031
        14.3.1. Hypertension
        14.3.2. Heart Failure
        14.3.3. Chronic Kidney Disease
        14.3.4. Diabetic Nephropathy
        14.3.5. Coronary Artery Disease
    14.4. Market Value Forecast, by Distribution Channel, 2017–2031
        14.4.1. Hospital Pharmacies
        14.4.2. Retail Pharmacies
        14.4.3. Online Pharmacies
    14.5. Market Value Forecast, by Country/Sub-region, 2017–2031
        14.5.1. GCC Countries
        14.5.2. South Africa
        14.5.3. Rest of Middle East & Africa
    14.6. Market Attractiveness Analysis
        14.6.1. By Drug Class
        14.6.2. By Indication
        14.6.3. By Distribution Channel
        14.6.4. By Country/Sub-region
15. Competition Landscape
    15.1. Market Player – Competitive Matrix (by tier and size of companies)
    15.2. Market Share Analysis, by Company (2022)
    15.3. Company Profiles
        15.3.1. Novartis AG
            15.3.1.1. Company Overview
            15.3.1.2. Drug Class Portfolio
            15.3.1.3. SWOT Analysis
            15.3.1.4. Financial Overview
            15.3.1.5. Strategic Overview
        15.3.2. Pfizer, Inc.
            15.3.2.1. Company Overview
            15.3.2.2. Drug Class Portfolio
            15.3.2.3. SWOT Analysis
            15.3.2.4. Financial Overview
            15.3.2.5. Strategic Overview
        15.3.3. AstraZeneca plc
            15.3.3.1. Company Overview
            15.3.3.2. Drug Class Portfolio
            15.3.3.3. SWOT Analysis
            15.3.3.4. Financial Overview
            15.3.3.5. Strategic Overview
        15.3.4. Merck & Co., Inc.
            15.3.4.1. Company Overview
            15.3.4.2. Drug Class Portfolio
            15.3.4.3. SWOT Analysis
            15.3.4.4. Financial Overview
            15.3.4.5. Strategic Overview
        15.3.5. Sanofi S.A.
            15.3.5.1. Company Overview
            15.3.5.2. Drug Class Portfolio
            15.3.5.3. SWOT Analysis
            15.3.5.4. Financial Overview
            15.3.5.5. Strategic Overview
        15.3.6. Bristol-Myers Squibb Company
            15.3.6.1. Company Overview
            15.3.6.2. Drug Class Portfolio
            15.3.6.3. SWOT Analysis
            15.3.6.4. Financial Overview
            15.3.6.5. Strategic Overview
        15.3.7. Daiichi Sankyo Company, Limited
            15.3.7.1. Company Overview
            15.3.7.2. Drug Class Portfolio
            15.3.7.3. SWOT Analysis
            15.3.7.4. Financial Overview
            15.3.7.5. Strategic Overview
        15.3.8. Takeda Pharmaceutical Company Limited
            15.3.8.1. Company Overview
            15.3.8.2. Drug Class Portfolio
            15.3.8.3. SWOT Analysis
            15.3.8.4. Financial Overview
            15.3.8.5. Strategic Overview
        15.3.9. Boehringer Ingelheim GmbH
            15.3.9.1. Company Overview
            15.3.9.2. Drug Class Portfolio
            15.3.9.3. SWOT Analysis
            15.3.9.4. Financial Overview
            15.3.9.5. Strategic Overview
        15.3.10. Johnson & Johnson
            15.3.10.1. Company Overview
            15.3.10.2. Drug Class Portfolio
            15.3.10.3. SWOT Analysis
            15.3.10.4. Financial Overview
            15.3.10.5. Strategic Overview

List of Tables

Table 01: Global RAS-acting Agents Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 02: Global RAS-acting Agents Market Size (US$ Mn) Forecast, by Indication, 2017–2031

Table 03: Global RAS-acting Agents Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 04: Global RAS-acting Agents Market Size (US$ Mn) Forecast, by Region, 2017–2031

Table 05: North America RAS-acting Agents Market Size (US$ Mn) Forecast, by Country, 2017–2031

Table 06: North America RAS-acting Agents Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 07: North America RAS-acting Agents Market Size (US$ Mn) Forecast, by Indication, 2017–2031

Table 08: North America RAS-acting Agents Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 09: Europe RAS-acting Agents Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 10: Europe RAS-acting Agents Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 11: Europe RAS-acting Agents Market Size (US$ Mn) Forecast, by Indication, 2017–2031

Table 12: Europe RAS-acting Agents Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 13: Asia Pacific RAS-acting Agents Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 14: Asia Pacific RAS-acting Agents Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 15: Asia Pacific RAS-acting Agents Market Size (US$ Mn) Forecast, by Indication, 2017–2031

Table 16: Asia Pacific RAS-acting Agents Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 17: Latin America RAS-acting Agents Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 18: Latin America RAS-acting Agents Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 19: Latin America RAS-acting Agents Market Size (US$ Mn) Forecast, by Indication, 2017–2031

Table 20: Latin America RAS-acting Agents Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 21: Middle East & Africa RAS-acting Agents Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 22: Middle East & Africa RAS-acting Agents Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 23: Middle East & Africa RAS-acting Agents Market Size (US$ Mn) Forecast, by Indication, 2017–2031

Table 24: Middle East & Africa RAS-acting Agents Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

---